Northern Capital Management (Wisconsin)’s Puma Biotechnology PBYI Stock Holding History

Northern Capital Management (Wisconsin)’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-8,643	Closed	-$322K	–	151
2017 Q1	$322K	Sell	8,643 -2,635	-23%	-$96.1K	0.13%	130
2016 Q4	$346K	Buy	11,278 +2,790	+33%	+$121K	0.14%	120
2016 Q3	$569K	Sell	8,488 -7,800	-48%	-$394K	0.26%	105
2016 Q2	$485K	Buy	16,288 +190	+1%	+$5.94K	0.22%	108
2016 Q1	$473K	Buy	16,098 +7,845	+95%	+$354K	0.21%	111
2015 Q4	$647K	Buy	8,253 +190	+2%	+$14.9K	0.28%	105
2015 Q3	$608K	Buy	8,063 +4,132	+105%	+$391K	0.26%	107
2015 Q2	$459K	Buy	3,931 +2,886	+276%	+$523K	0.21%	107
2015 Q1	$247K	Buy	+1,045	New	+$223K	0.12%	124

Other funds holding PBYI

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Capital Management (Wisconsin)'s PBYI Position: Q2 2017 in Review

Northern Capital Management (Wisconsin) sold out of Puma Biotechnology (PBYI) in Q2 2017, closing a stake of 8,643 shares — an estimated $322K sold.

Northern Capital Management (Wisconsin) first reported a position in PBYI in Q1 2015 and held it in 9 quarters. The position peaked at $647K in Q4 2015. 154 funds tracked by Wall St. Rank hold PBYI as of Q2 2017.

Northern Capital Management (Wisconsin) reported no remaining Puma Biotechnology position as of Q2 2017 after selling out during the quarter.
Northern Capital Management (Wisconsin) sold 8,643 Puma Biotechnology shares in Q2 2017, an estimated $322K.
Northern Capital Management (Wisconsin) first reported a position in Puma Biotechnology in Q1 2015 and held it in 9 quarters.
Northern Capital Management (Wisconsin)'s Puma Biotechnology position peaked at $647K in Q4 2015.
154 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2017.

Based on Northern Capital Management (Wisconsin)'s 13F filing for Q2 2017, filed 9 Aug 2017.